Core Viewpoint - Quantum BioPharma Ltd. announces a $5 million Reg D 506(c) offering through its licensee Unbuzzd Wellness Inc., which has developed a beverage that accelerates alcohol metabolism and reduces hangover symptoms, with no dilution for Quantum BioPharma shareholders [1][4]. Company Overview - Quantum BioPharma is focused on innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with drug candidates at various development stages [1][8]. - The company retains a 20.10% ownership stake in Unbuzzd Wellness Inc. and is entitled to a 7% royalty on sales until reaching $250 million, after which the royalty will decrease to 3% [8]. Unbuzzd Wellness Inc. Details - Unbuzzd Wellness Inc. is a public issuer specializing in wellness and recovery supplements, with a product designed to enhance alcohol metabolism and cognitive function [5][8]. - The beverage, unbuzzd, is backed by clinical research and aims to meet consumer needs for responsible drinking [3][5]. Clinical Trial Findings - A clinical trial demonstrated that unbuzzd accelerates alcohol metabolism, reducing blood alcohol concentration (BAC) by over 40% faster within 30 minutes compared to control subjects [6][12]. - Participants reported significant improvements in alertness and cognitive performance shortly after consuming unbuzzd, with no adverse side effects noted [6][12]. Investor Webinar - An investor webinar is scheduled for October 30, 2025, where Unbuzzd leadership will discuss the investment opportunity and plans for scaling distribution [2][3]. - The offering is targeted at accredited investors, aiming to expand direct-to-consumer and retail availability, with potential plans for an IPO [3].

Core Viewpoint - Quantum BioPharma Ltd. announced that its licensee, Unbuzzd Wellness Inc., will host an Investor Webinar to discuss their innovative beverage designed to accelerate alcohol metabolism and reduce hangover symptoms, highlighting a significant investment opportunity [1][2][3]. Company Overview - Quantum BioPharma is a biopharmaceutical company focused on developing innovative solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [1][7]. - The company retains a 20.10% ownership stake in Unbuzzd Wellness Inc. and is entitled to a 7% royalty on sales from the unbuzzd beverage until total payments reach $250 million, after which the royalty will decrease to 3% [7]. Product Details - Unbuzzd is a scientifically-proven beverage that accelerates alcohol metabolism, restores mental clarity, and alleviates hangover symptoms [1][5]. - The product is backed by a double-blind, placebo-controlled clinical trial demonstrating that unbuzzd reduces blood alcohol concentration (BAC) by over 40% faster within 30 minutes compared to control subjects [5]. - Participants reported significant improvements in alertness and reductions in perceived impairment and hangover symptoms, including a 67% reduction in headache severity at four hours post-consumption [5][6]. Investment Opportunity - Unbuzzd Wellness Inc. is currently offering a Regulation D 506(c) investment opportunity, aiming to raise up to $5 million to support its expansion plans and potential initial public offering [3]. - The webinar will provide insights into the company's strategies for increasing direct-to-consumer, distributor, and retail sales [2][3].